Camurus is a brand-new company record, and its full research profile isn't ready yet.
camurus.comCrawled Oct 26, 2026
Camurus focuses on treating diseases of the central nervous system, rare diseases, endocrine disorders, oncology, and supportive care.
Camurus’ FluidCrystal injection depot technology enables sustained drug release over extended periods.
Camurus’ Medical Hub offers healthcare professionals access to medical materials, such as congress posters, symposia recordings, and slide decks, related to its disease areas.
Camurus’ FluidCrystal-based products target unmet medical needs to improve treatment outcomes and quality of life for patients.
The surgery was a turning point: his hands and feet shrank, his features softened, and his confidence grew. He says it felt "like a plug being lifted from my soul." It was a huge shift, not just medically, but in how he experienced himself.
“When I was told I had a brain tumor, I freaked out and went into a mini shock”, Darro says. “I couldn’t believe what was happening and I was afraid. When the doctors listed off the possibilities of what the tumor could be, including cancer, I lost it.”
At 41, Dusty received a diagnosis that changed the course of her life. What was first thought to be advanced pancreatic cancer turned out to be GEP-NET – a subtype of neuroendocrine tumors. This is her story of finding answers, overcoming fear, and learning to live with a chronic condition.
Jack sought help for his impaired vision. What he found was the answer to changes in his body he had barely noticed creeping up on him, all caused by a tumor on his pituitary gland.
Lund — 30 March 2016 — Camurus AB (Nasdaq Stockholm: CAMX) today announces that the Annual Report for 2015 now is available at the company’s website: www.camurus.com
Camurus provides downloadable logos and high-resolution images for publications.
Camurus offers contact options, including phone and email.
Camurus offers job opportunities and insights into working at the company.
Camurus develops innovative medical products to improve the lives of patients with severe and chronic diseases.
Fredrik Tiberg (born 1963) is Camurus’ president & Chief Executive Officer since 2003, and member of the Board since 2002. He is also member of the Science and Development Committee.
Hege Hellström (born 1965) is Board member since 2020. She is also member of the Audit Committee.
Jakob Lindberg (born 1972) is Board member since 2021. He is also chairman of the Remuneration Committee.
Camurus is a Swedish pharmaceutical company developing long-acting medicines for severe and chronic diseases.
Camurus uses FluidCrystal technology and cross-functional R&D expertise to develop long-acting treatments for severe and chronic diseases, either in-house or through partnerships.
The interim report January-September is published at 7.00 am CET on 5 November 2026.
Camurus develops long-acting medicines to improve the lives of patients with severe and chronic diseases, supporting patients, caregivers, and society.
Raising a concern Whistleblowing platform
To contact Camurus Inc, please email: [email protected]
Camurus provides updated financial information to help users understand its business and performance.
Camurus offers a whistleblower platform for reporting misconduct.
Camurus is a Swedish science-led biopharmaceutical company committed to improving the lives of patients with severe and chronic diseases.
US homepage for Camurus, a Swedish science-led biopharmaceutical company committed to improving the lives of patients with severe and chronic diseases.
Camurus Inc, a U.S. affiliate of Camurus AB, details the categories of Consumer Health Data it collects under state privacy laws.